The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antifungal Susceptibility Testing has newly introduced species-specifi c clinical breakpoints (CBPs) for fl uconazole and voriconazole. When CBPs can not be determined, wild-type minimal inhibitory concentration (MIC) distributions are detected and epidemiological cutoff values (ECVs) provide valuable means for the detection of emerging resistance. The aim of this study is to determine triazole resistance patterns in Candida species by the recently revised CLSI CBPs. A total of 140 Candida strains isolated from blood cultures of patients with invasive candidiasis hospitalized in various intensive care units in Turkey and sent to our reference laboratory between 20112012, were included in the study. The isolates were identifi ed by conventional methods, and susceptibility testing was performed against fl uconazole, itraconazole and voriconazole, by the 24-h CLSI broth microdilution (BMD) method. Azole resistance rates for all Candida species were determined using the new species-specifi c CLSI CBPs and ECVs criteria, when appropriate. The species distribution of the isolates were as follows; C.parapsilosis (n= 31 ), C.tropicalis (n= 26 ), C.glabrata (n= 21), C.albicans (n= 18), C.lusitaniae (n= 16), C.krusei (n= 16), C.kefyr (n= 9), C.guilliermondii (n= 2), and C.dubliniensis (n= 1). According to the newly determined CLSI CBPs for fl uconazole and C.albicans, C.parapsilosis, C.tropicalis [susceptible (S), <= 2 ?g/ml; dose-dependent susceptible (SDD), 4 ?g/ml; resistant (R), >= 8 ?g/ml], and C.glabrata (SDD, <= 32 ?g/ml; R>= 64 ?g/ml) and for voriconazole and C.albicans, C.parapsilosis, C.tropicalis (S, <= 0.12 ?g/ml; SDD, 0.25-0.5 ?g/ml; R, >= 1 ?g/ml), and C.krusei (S, <= 0.5 ?g/ml; SDD, 1 ?g/ml; R, >= 2 ?g/ml), it was found that three of C.albicans, one of C.parapsilosis and one of C.glabrata isolates were resistant to fl uconazole, while two of C.albicans and two of C.tropicalis were resistant to voriconazole. The ECVs of 0.5 ?g/ml for voriconazole and C.glabrata were used to differentiate wild-type (MIC <= ECV) from non-wild-type (MIC > ECV) strains. Five of C.glabrata were non-WT for voriconazole. Due to the lack of CBPs for the less common species, the ECVs for fl uconazole, itraconazole and voriconazole, respectively, were used for C.lusitaniae (2 ?g/ml, 0.5 ?g/ml, 0.03 ?g/ml), C.guilliermondii (8 ?g/ml, 1 ?g/ml, 0.25 ?g/ml), C.dubliniensis (0.5 ?g/ml, 0.25 ?g/ml, 0.03 ?g/ml), and C.kefyr (1 ?g/ml, 0.015 ?g/ml) to categorize isolates of these species as wildand non-wild-type. When the ECVs were used for fl uconazole, one each of C.lusitaniae, C.dubliniensis and C.kefyr; for voriconazole, three of C.lusitaniae and one of C.kefyr were detected as non-wild-type. Overall, a total of fi ve Candida species were resistant to fl uconazole and four to voriconazole and among these species one each of C.parapsilosis, C.tropicalis, C.glabrata, C.lusitaniae, C.kefyr and three of C.albicans exhibited cross-resistance at least against two azoles. It was concluded that, the strains identifi ed as resistant and non-wild-type in this in vitro study should be supported by molecular and in vivo studies for the determination of their clinical validity